Turns Out, The Cure Was The Easy Part

I met a young woman in Geneva last year. Mid-20s, poised, bright. She had sickle cell disease and told me her childhood had been a blur of hospital beds and missed school years.

Then she mentioned something I didn’t expect. She was part of a Casgevy clinical trial. No crises in over two years. She was working full-time, traveling, and hadn’t touched morphine since the infusion.

That moment clarified what CRISPR Therapeutics (CRSP) had actually accomplished. And yet here we are in 2026, and the stock market still hasn’t figured it out.

Casgevy isn’t a research milestone. It is a commercial therapy with global approvals, real patients, and durable outcomes.In sickle cell disease, treated patients have remained free from vaso-occlusive crises for nearly three years on average.

In transfusion-dependent beta thalassemia, nearly every patient has achieved long-term transfusion independence. This isn’t incremental medicine. It’s a full reset in clinical expectations.

Investors aren’t skeptical of the science. The hesitation is about delivery. Casgevy is a complex, multi-step therapy that requires stem cell mobilization, collection, ex vivo editing, chemotherapy-based conditioning, reinfusion, and extended monitoring.

The entire process takes several months. The price is $2.2 million per patient. This doesn’t scale the way most drugs do, and expecting a fast commercial curve was always unrealistic.

Instead, the rollout has followed a deliberate pace. Treatment centers have been coming online steadily, with 75 now activated globally.

By the end of Q3 2025, 165 patients had begun treatment. Vertex (VRTX) reported over $60 million in year-to-date Casgevy revenue and guided to more than $100 million for the full year.

These numbers reflect infrastructure capacity, not demand ceilings. Behind them are growing referral pipelines, improving reimbursement systems, and physicians becoming more comfortable offering a one-time curative treatment.

CRISPR Therapeutics receives 40% of Casgevy revenue. If 300 patients are treated in 2026, the company could generate around $185 million in net revenue after standard discounts.

At a modest growth rate, Casgevy alone could support several hundred million dollars in annual revenue by decade’s end.

The total addressable population across approved regions is about 60,000. Treating just a few percent of that group each year turns Casgevy into a multi-billion-dollar therapy.

Even after applying discounts and accounting for Vertex’s share, CRISPR could see more than $1 billion annually from this product alone. That outcome would justify the current market cap without including anything else in the pipeline.

But the pipeline is moving too. CTX-310 has shown large reductions in LDL and triglycerides by targeting ANGPTL3. It’s now progressing into Phase 1b for cardiometabolic disease.

Safety issues elsewhere in the in vivo gene editing space have made investors more cautious, but CRISPR’s results have remained clean.

CTX-112, the company’s allogeneic CAR-T program, is also advancing. In relapsed lymphoma, including patients who failed prior CAR-T therapy, response rates have been strong. Early data in autoimmune conditions is encouraging, and further updates are expected later this year.

Then there is CTX-211, the hypoimmune diabetes program. It has remained relatively quiet but is now in clinical development.

Competing programs from companies such as Sana Biotechnology (SANA) and Seraxis in diabetes cell replacement, along with broader gene editing peers like Beam Therapeutics (BEAM), Intellia Therapeutics (NTLA), Prime Medicine (PRME), and Precision BioSciences (DTIL), have all shown how quickly sentiment can shift when proof of concept arrives.

Even with a crowded field, CRISPR is positioned to lead as the data matures.

The company continues to run losses, as expected. It posted a net loss of $451 million through the first nine months of 2025 and will continue raising capital. Dilution is a factor.

But with a cash runway extending into 2028, it has room to advance its pipeline without being forced into reactive decisions.

Casgevy is not a forward-looking bet. It is already producing measurable outcomes, already generating revenue, and already forcing a shift in treatment strategy for two previously intractable diseases.

The market’s caution reflects operational friction, not clinical uncertainty. As treatment access expands and outcomes continue to validate, that gap will close.

For patients, it already has. The woman I met in Geneva beat her disease two years ago. The market is still catching up.